Glioblastoma (GBM) is the most aggressive human cancer, with a median survival ranging from 12-18 months from time of diagnosis and a nearly 100% local recurrence rate following maximal therapy. 1, 2 One very important step in managing GBM is identifying noninvasive methods that predict response to therapy and detect early tumor recurrence so that early adaptive treatment measures can be instituted.
The histopathological hallmark of malignant transformation to a GBM is the presence of vascular proliferation. 3 It is this highly vascularized nature of GBMs that has resulted in significant interest in anti-angiogenic therapy (AATx) to control tumor progression and recurrence. 4 Vascular endothelial growth factor (VEGF) is the central factor in regulating GBM neovascularization; therefore, strategies that inhibit VEGF have been explored the most. 5 Bevacizumab (Avastin), a humanized monoclonal antibody against VEGF-A, is currently accepted as therapy for recurrent GBMs, 6 and there is some consideration to its use upfront as a primary line of therapy at the time of diagnosis. 7 Another VEGF inhibitor, VEGF-trap, an engineered VEGF receptor that selectively binds to and inhibits "free" VEGF, has also been shown to be effective in preclinical models of GBM. 8, 9 More recent approaches have explored alternate classes of AATx compounds including multi-tyrosine kinase Fig. 1 . Growth rate of intracranial GBM xenografts in response to 2 anti-angiogenic therapies (AATx) used as monotherapy or as combinatorial therapy with radiation therapy (RT). (A) Mouse intracranial xenografts were generated using GSC-1 (i) and U87 (ii) cell lines, and changes in tumor volume were compared longitudinally between these tumor models. (B) U87 xenografts were treated with AATxs (sunitinib or VEGF-trap), RT alone, or AATx + RT. Tumor volumes were measured using T 2 w-MRI images on days 7, 10, 14, 17, and 21 post tumor implantation. Line graphs (i, ii) are representative of relative tumor volume normalized to baseline tumor (day 7) in control and experimental groups. Bar graphs (iii) compare the relative tumor inhibitors such as sunitinib, 10 which has been shown to reduce glioma tumor growth in GBM xenografts. 11, 12 Despite the attractive mechanistic approach of AATx therapy in a highly vascularized tumor, clinical experience to date suggests that AATx drugs have not significantly increased the survival of GBM patients. Bevacizumab, despite demonstrating initial clinical improvements and radiological response, has shown transient benefits, and GBM recurrence is inevitable, often with a much more invasive phenotype. 13 -15 Use of VEGF-trap has been associated with some radiological response, but without any significant improvement in recurrent GBM. 16 Similarly, sunitinib has failed to show benefits in improving progression-free survival in GBMs. 17 The ability to detect recurrence early, prior to a more aggressive phenotype, is critical for initiating alternative targeted therapies. Furthermore, it is now believed that the efficacy of AATx can be potentiated if it is combined with standard chemotherapy, radiation therapy (RT), or other targeted therapies. 18, 19 Establishing noninvasive biomarkers that can accurately detect the response to different classes of AATx is important and may be useful for scheduling combinatorial therapy.
Multiparametric MRI provides a promising noninvasive strategy to characterize cellular and vascular properties of tumors in addition to defining response to chemotherapy, RT, and AATx therapies. 20 -22 For instance, parameters derived from perfusion MRI have been used to assess response to AATx therapies in patients diagnosed with GBM. 23 Diffusion MRI parameters have shown value in predicting survival outcome in patients with recurrent GBM who are treated with bevacizumab. 24 However, to date there has been no clinical or preclinical studies that directly compare various MRI parameters in response to different classes of AATx. Clinical studies are limited in their ability to obtain repeat multiple biopsies at the time of perceived tumor recurrence. As such, preclinical studies provide the advantage of making direct comparison between specific MRI parameters and tumor characteristics in response to various classes of AATx. In this study, we focused on establishing MRI parameters that are indicative of tumor cellularity, growth, and vascularity in response to AATx when administered as monotherapy or in combination with RT and evaluating these MRI parameters across different classes of AATxs in preclinical models of GBM. Findings from this study could be used to inform directed questions in the clinical setting using cohorts of patients followed serially with frequent MRI imaging that compares clinical outcome and tumor progression with MRI and dynamic contrast-enhanced (DCE)-based parameters.
Materials and Methods

Cells and Transfection
We used 2 different GBM cell lines for this study. One, an established human glioma stem cell line U87 (ATCC, Rockville) and the other, a glioma stem cell line (GSC-1) obtained from a human GBM tumor specimen at The University of Texas MD Anderson Cancer Center (Houston), as previously described. 25 To generate stable U87 or GSC-1 cell lines with VEGF-trap expression, cells were transfected with VEGF-trap using a PiggyBac transposon system (provided by Dr. Nagy), as previously described. 26 
Intracranial Xenograft Models of Glioblastoma Multiforme
All animal experiments were carried out according to institutional Animal Care Committee guidelines. Intracranial xenografts were generated, as described previously. 27 Seven days post U87 cell implantation and 21 days post GSC-1 cell implantation, we used baseline MRI to ensure equal tumor sizes prior to instituting treatment. We ensured successful intracranial expression of VEGF-trap in-vivo by imaging the sectioned brain ex-vivo (Supplementary Fig. S1 ).
Anti-angiogenic Therapy
In order to allow direct one-to-one comparison of the effects of AATx with a sufficient number of animals for each group, we limited the time window of the comparison to 10 days of treatment (days 7 -17), starting 1 week following tumor cell implantation. Each treatment arm included 8 -10 mice repeated in duplicate, and the AATxs evaluated here included sunitinib, VEGF-trap, and B20, which is the mouse equivalent of bevacizumab or Avastin (Genentech). Sunitinib (Pfizer) was prepared as previously reported, 28 and a dose of 40 mg/kg/day was administered by oral gavage. Mice implanted with U87:VEGF-trap cells were given 3 mg/mL doxycycline (Sigma) in drinking water. B20 was administered intraperitoneally (150 mg/mouse) every 3 days. The onset of treatment remained the same for all AATxs. To study the immediate effects of eliminating VEFG-trap on physiological characteristics of tumor vasculature, the supply of doxycycline was stopped between days 17 and 21 post intracranial implantation of the U87:VEGF-trap cells. The tumors were allowed to grow until the mice became moribound and were euthanized according to animal care protocols.
Radiation Therapy
A single fraction of 8 Gy radiation was delivered at day 8 following intracranial injection using a cone-beam CT image-guided small animal irradiation system (XRT225Cx, Precision X-Ray, Inc), in which mice were positioned in an in-house, custom-built stereotactic immobilization device, as previously described. 29, 30 Magnetic Resonance Imaging radiofrequency transmission, as detailed previously. 29 Multiparametric MRI was used to detect real-time changes in physiological properties of a tumor in response to single-agent or combinatorial therapy with AATx at days 7, 10, 14, and 17 after intracranial tumor implantation. The acquisition of multiparametric MRI images and analysis of cerebral blood flow (CBF) are described in Supplementary Material.
Magnetic Resonance Image Analysis
MIPAV software (National Institutes of Health) was used to analyze the MRI images. Tumor region of interest (ROI) on T 2--weighted (T 2 w) images was manually defined and used to measure the tumor volume. For contrast enhancement analysis, the percentage increase in contrast enhancement of the tumor ROI on T 1 -weighted (T 1 w) + contrast images was normalized to adjacent nontumor region. Apparent diffusion coefficient (ADC) and dynamic contrast enhanced (DCE) maps were generated from diffusion (DWI) or DCE-MRI images. Tumor ROIs on T 1 w + contrast or T 2 w images were transposed to corresponding diffusion and DCE maps. For diffusion analysis, percentage change in ADC value of tumor, as compared with similar contralateral region, was calculated based on evidence of improved motion sensitivity. 29 Contrast enhancement of the regions that were overlapping with ventricles was excluded from analysis. For DCE analysis, tumor ROI and arterial input function were selected, propagated to all time points on each slice, and used for extraction of contrast enhancement. Average contrast enhancement data and DCE tool v1.04 (www.TheDCETool.ca) were used to calculate the initial area under the contrast enhancement curve (iAUC). The concentration of contrast agent in tumor region over time was calculated using modified Tofts model kinetic analysis.
Immunostaining
Immunostaining was performed on cryopreserved frozen brain sections of control and treated animals using anti-human primary antibodies including anti-CD31 (1:500, BD Pharmingen), anti-Ki67 (1:25, Dako), anti-angiopoietin-1 (Ang-1) (1:100, Santa Cruz Biotechnology), and anti-angiopoietin 2 (Ang-2) (1:100, Santa Cruz Biotechnology) per manufacturer's' protocol. Cell density and microvascular density (MVD) were calculated by counting the number of cell nuclei on hematoxylin-and-eosin stained sections and CD31-positive vessels per 10 high power field (40X), respectively. Vessel diameter was measured using Mirax scan software.
Laser Capture Microscopy
Frozen sections (5 mm) were dehydrated through alcohol and xylene and air-dried for 15 minutes. Laser capture microscopy (LCM) slide was loaded into the microscope (MMI Cellcut system mounted on a Zeiss Axiovert 200 M microscope with a 340 nm laser and a Sony 3-CCD camera) holder. CD31 immunostaining was used to delineate tumor vessels. In the bright field channel, the LCM cap was lowered onto the sample. Vessels were circled on the software, and then the laser was used to cut through the tissue twice. A minimum of 15 vessels was collected for each sample.
PicoPure RNA Isolation, cDNA Synthesis and Quantitative Real-Time PCR Analysis RNA was extracted from LCM-isolated vessels using PicoPure RNA extraction kit (Applied Biosciences). cDNA synthesis and quantitative real-time PCR (qPCR) analysis were performed using SuperScript VILO kit (Invitrogen) and Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) according to the manufacturer's' protocol.
Statistical Analysis
Data were represented as mean+standard error. The Student' paired t test was used to analyze the significant difference at each time point from baseline between 2 experimental groups. Analysis of variance (ANOVA) was used for comparisons between multiple treatment groups, and P, .005 was considered as significant difference.
Results
GBM Growth in Response to Different Classes of AATxs Used as Monotherapy or Combinatorial Therapy
MRI Biomarkers
Apparent Diffusion Coefficient
To allow one-to-one direct comparison between effects of sunitinib and VEGF-trap as monotherapy or as combinatorial therapy with RT, we selected a 10-day treatment time window. Normalized baseline (day 7) ADC values were similar for all treatment groups ranging from 9%-13% higher values than contralateral brain parenchyma. Treatment with RT or AATx + RT resulted in a significant rise in ADC from baseline compared with control. ADC values at day 17 were above baseline as follows; RT: 35%+5%; sunitinib + RT: 35%+5%; VEGF-trap + RT: 43%+8%; (P , .01). While the magnitude ADC rise above control was greater with VEGF-trap + RT compared with sunitinib + RT, this difference was not statistically significant. ADC values in response to sunitinib or VEGF-trap monotherapy were similar to the control group (day 17 sunitinib: 23%+3%; VEGF-trap: 24%+2%) (Fig. 1C) .
We used Ki67 as a marker for cell proliferation to study whether reduced tumor growth rate and alterations in ADC are associated with a reduction in tumor cell proliferation. We found a statistically significant reduction in the number of proliferating cells in all treatment arms compared with the control group at day 17 ( Fig. 1Di, P , .0001) . We examined tumor cell density in response to different treatment regimens at day 17. Tumor cell density did not change significantly in response to sunitinib or VEGF-trap but was significantly reduced with RT or combinatorial therapies (Fig. 1Dii, P , .001) . The percentage reduction in cell density was 34% in RT, 32.9% in sunitinib + RT, and 48.7% in VEGF-trap + RT.
Contrast enhancement on T 1 w + contrast and DCE-MRI images
Contrast enhancement on T 1 w + contrast MRI images is used in clinical practice to determine tumor growth and overall volume. We first examined contrast enhancement of the U87 and GSC-1 tumors on contrast MRI images at early and late stages of tumor development. The pattern of contrast enhancement was significantly different between the 2 models. U87 tumors showed early and almost uniform signal enhancement throughout at all stages of tumor development (Fig. 2Ai and B) , while, an increase in contrast enhancement in GSC-1 tumors was detected only at later stages of tumor development, with significantly heterogeneous enhancement (Fig. 2Ai) . Therefore, analysis for longitudinal changes in contrast enhancement was carried out on U87 tumors on days 7 -17, and analysis for GSC-1 tumors focused to days 40 -50, during the period in which contrast enhancement was evident in this model.
Monotherapy with VEGF-trap or combinatorial therapy with VEGF-trap + RT resulted in the most significant reduction in contrast enhancement on T 1 w images compared with other treatment groups. Most notably, there was a distinct loss of enhancement on DCE images, while T 2 w images continued to show the presence of tumor in these groups (Fig. 2Aii) . The loss of DCE enhancement was very specific to VEGF-trap treatment, as sunitinib-treated animals showed no significant change on DCE enhancement. Quantification analysis on T 1 w + contrast images indicated a significant reduction in contrast enhancement with VEGF-trap or VEGF-trap + RT treatment (P , .05 for VEGFtrap and P , .001 for VEGF-trap + RT). The reduction occurred early in response to treatment and remained decreased throughout therapy. Importantly, contrast enhancement did not significantly change in response to sunitinib or sunitinib + RT as compared with control groups (Fig. 2B) . We confirmed similar results in GSC-1 with VEGF-trap treated tumors showing significant reduction in signal enhancement (P , .05) on T 1 w + contrast and DCE images ( Fig. 5B and C) .
We further investigated the correlation of contrast enhancement to changes in tumor growth and found no correlation between these 2 parameters (Fig. 2C) .
Alteration in Tumor Vessel Permeability With Use of Monotherapy or Combinatorial Therapy with AATxs
To evaluate longitudinal changes in vessel permeability in response to monotherapy or combinatorial therapy with AATx, we measured iAUC, which is considered to be an indicator of both tumor vessel permeability and vessel perfusion. 31 In both control and RT-treated U87 tumors, the percentage change in iAUC was not significantly different from baseline at each stage of tumor growth (Fig. 3A) . Monotherapy with sunitinib reduced iAUC from baseline (35% reduction) at day 10; however, levels returned back to control at later stages of tumor growth (beyond day 12). Combinatorial therapy with sunitinib + RT reduced iAUC level from baseline (40% reduction) at day 10, and this reduction persisted on all treatment days (Fig. 3Ai) . With use of VEGF-trap or VEGF-trap + RT, there was a significantly greater reduction in iAUC from baseline (between 70% -85% reduction, P , .05) on all treatment days (Fig. 3Aii) . Comparison of contrast agent Fig. 3 . Dynamic contrast-enhanced (DCE)-MRI parameters in response to monotherapy and combinatorial therapies using 2 classes of anti-angiogenic therapies (AATx). (A) Line graphs represent logarithmic scale of percentage change in initial area under the contrast enhancement curve (iAUC) from baseline for each treatment group (i, ii). Significant differences from baseline are represented as *P , .01 and **P , .0001. Representative plots show dynamics of contrast agent concentration for the tumors treated with sunitinib (iii) or VEGF-trap (iv) treatment regimens. (B) Mice were given doxycycline (+Dox) to induce VEGF-trap expression starting 7 days post tumor implantation; doxycycline was discontinued (-Dox) on days 17-21 to turn off VEGF-trap expression and resumed on days 21-35 to turn VEGF-trap on again. T 2 w-MRI images show continuous tumor growth, and DCE and T 1 w + contrast MRI images show the contrast enhancement at each time point (white arrows). (C) Mice were treated with B20 (150 mg/mouse) for 10 days, and then the drug administration was discontinued. MRI images were acquired during B20 treatment at day 17 (+B20) and after drug discontinuation at days 21 and 31 (-B20). T 2 w images represent the presence and growth of the tumor, and DCE and T 1 w + contrast images show contrast enhancement at the tumor region (white arrows) (i). Bar graphs (ii) show percentage change in contrast enhancement at tumor region compared with adjacent normal brain region. Due to limited survival of control mice, contrast enhancement at day 31 was calculated only for B20 treated animals that survived longer. Significant differences in contrast enhancement between control and B20-treated animals are represented as *P , .05 and **P , .001.
Fig. 4. Histological analysis of tumor vascularity in response to anti-angiogenic therapies (AATx therapy). (A)
Immunohistochemical staining shows CD31-positive tumor microvessels in control and treated animals at day 17 post intracranial injection (i). Bar graphs represent microvessel density (MVD) per 10 high power field (40X) (ii,iii). Significant difference between control and treatment groups at each time point is represented as *P , .0001 and **P , .00001. Mice treated with B20 for 10 days; MVD was determined during drug treatment (day 17, +B20) and 2 weeks after drug discontinuation (-B20) (iv). Bar graph (v) represents MVD, and significant difference from control group is represented as *P , .0001. Scale bar: Jalali et al.: MRI biomarkers for Anti-angiogenic therapy in GBM Neuro-Oncologyconcentration-time curves between different treatment groups indicated a complete inhibition of contrast agent accumulation following VEGF-trap treatment (Fig. 3Aiii and iv) . Similarly, quantitative analysis of vessel permeability indicated a significant decrease (P , .01) in iAUC in VEGF-trap treated GSC-1 tumors compared with control group (Fig. 5D) .
Loss of Tumor Vessel Permeability in Response to VEGF-trap Treatment Is a Transient and Reversible Effect
We examined the duration by which the reduced contrast enhancement persisted upon discontinuation of VEGF-trap to better understand the kinetics of significant reduction or complete loss of contrast enhancement on T 1 w + contrast and DCE images, respectively. Three days following discontinuation of doxycycline, contrast enhancement on T 1 w + contrast and DCE-MR images increased back to levels comparable to those seen in the control animals. With return of enhancement, tumor volume remained unchanged and continued similar growth rate on T 2 w (Fig. 3B) . These results confirmed that reduction of contrast enhancement was directly dependent on VEGF-trap.
We repeated the experiments with another AATx, B20. Similar to VEGF-trap, B20 treatment also significantly reduced contrast enhancement (Fig. 3Ci) , supporting the loss of MRI enhancement being a direct consequence of VEGF inhibition. Similarly, the loss of contrast enhancement was reversed 3 days following B20 discontinuation (Fig. 3Cii) .
Alteration in Tumor Vascularity With Use of Monotherapy or Combinatorial Therapy with AATxs
To determine whether alteration in contrast enhancement is associated with changes in tumor vascularity, we determined MVD in addition to the CBF parameter on MRI (Fig. 4A) . In all treatment groups, there was a significant reduction in MVD at day 10 following therapy compared with control (P , .0001). This reduction in MVD returned to control levels at later stages of tumor growth in the sunitinib or RT-alone groups but remained decreased in the VEGF-trap, sunitinib + RT, or VEGF-trap + RT groups (Fig. 4Ai, ii & iii) . Similarly, tumor MVD significantly reduced in the groups treated with B20 compared with control (Fig. 4Aiv, v) (P , .001). There was no change in MVD within 3 days after discontinuation of VEGF-trap or B20, indicating that MVD alone does not explain the return of enhancement witnessed on T 1 w + contrast and DCE images. Furthermore, there was no relationship between the extent of contrast enhancement on T 1 w + contrast and MVD on any treatment day, eliminating the possibility that reduced contrast enhancement is mediated by a reduction in MVD.
We next investigated whether reduced contrast enhancement with VEGF inhibition was explained by a decrease in CBF. We found a significant decrease in CBF in VEGF-trap treated tumors compared with control nontreated tumors (control: 124.25+36.35 vs VEGF-trap: 67+11.2; P , .05) (Fig. 4Bi) . Associated with a decrease in CBF was an apparent compensatory dilation of GBM vasculature (Fig. 4Bii) . Vessel dilatation was seen predominantly at the tumor periphery, as defined by the junction between tumor and normal brain.
Characterization of Angiogenic Factors in Tumor Vasculature of VEGF-trap Treated Animals
We investigated change in expression of angiopoietins as an additional angiogenic class of molecules that closely interacts with VEGF during normal physiological and pathological vessel formation. 27, 32 There was an increased expression of Ang-1 in the center of the U87 tumors treated with VEGF-trap compared with control using both immunofluorescent and qPCR analysis (Fig. 4C) . Increased expression of Ang-1 was seen in both tumor cells and tumor vasculature (Fig. 4Ci, ii) . There was also an increased expression of Ang-2 following VEGF inhibition that was seen predominantly in dilated vessels evident in tumor periphery (Fig. 4Civ, v) .
Discussion
The use of AATx alone or in combination with RT for treatment of GBMs has been advocated for the past decade, with combinatorial therapy holding promise as a strategy that can improve response to either therapy used alone. 8, 18, 33 However, for effective use of combinatorial therapy in clinical practice, we need to establish proper noninvasive biomarkers that can predict response to therapy and may help with designing the precise scheduling of treatment strategies.
In this study, combinatorial therapy with VEGF-trap + RT showed a statistically significant reduction in tumor growth compared with sunitinib + RT. The level of growth suppression is clearly dependent on the class of AATx used, and the difference in effect of AATx can be explained by differences in mechanism of action of the 2 AATxs. 10, 15, 17, 34 The difference could also be a reflection of the efficiency of sunitinib in crossing the blood brain barrier, which may also explain in part why sunitinib fails to demonstrate benefit in GBM clinical trials as a single AATx. 15, 17 MRI parameters can provide noninvasive methods for assessing tumor growth and response to therapy. For instance, ADC maps, created based on DWI images, signify tumor cell density since high-cellular density restricts water diffusion. 35 We demonstrated a significant increase in ADC values for the groups treated with RTor sunitinib + RT (similar to our previous report) 29 or VEGF-trap + RT compared with control. Increased ADC values in response to RT have been reported in human glioma tumor xenografts and also in other tumor types such as hepatic carcinoma. 29, 36, 37 Interestingly, AATx alone or addition of AATx therapy to RT did not significantly affect ADC. This is in contrast with previously published data showing an early increase in ADC in response to sunitinib treatment in a U118 glioma mouse model, 38 or a late change in ADC in response to sorefenib therapy in nude rats with implanted U87 tumors. 39 These differing results can be explained by difference in tumor models and class of AATx used.
Associated with an increase in ADC, we found a parallel significant reduction in tumor cell density in the RT alone, sunitinib + RT, or VEGF-trap + RT groups as compared with control, with no significant change in cell density in response to AATx; this suggests that the increase seen in ADC is predominantly a reflection of reduced tumor cell density, which appears to be as a consequence RT alone. On the other hand, our results showed a reduction in cell proliferation index, Ki67, in all treatment groups. Therefore, we believe our results support that ADC is an accurate indicator of tumor cell density rather than tumor cell proliferation.
In addition to MRI parameters that reflect tumor growth and proliferation, we explored MRI parameters that reflect alterations in tumor vascularity. Using T 1 w + contrast and DCE-MRI, we observed a statistically significant reduction in contrast enhancement in tumors treated with VEGF-trap or VEGF-trap + RT without any association between changes in MVD and contrast enhancement. Although MVD was reduced in sunitinib, VEGF-trap, and B20-treated tumors, the reduction in contrast enhancement was seen only in VEGF-trap and B20-treated tumors. Therefore, alternative parameters beyond MVD, such as vessel blood flow, Jalali et al.: MRI biomarkers for Anti-angiogenic therapy in GBM perfusion, or permeability may explain reduced or complete loss of enhancement on T 1 w + contrast or DCE images. Most notably, we found that loss of contrast enhancement did not correlate with decrease in tumor growth or overall tumor volume. This finding is in agreement with previous data indicating that a reduction in contrast enhancement in response to AATx limits the interpretation of the extent of contrast enhancement on T 1 w + contrast MRI images as a reliable predictor of tumor growth while on treatment with AATx. 16, 40, 41 The differences seen in contrast enhancement more closely paralleled the MRI parameters indicative of vessel permeability. DCE-MRI is considered to reflect physiological characteristics of tumor vasculature such as perfusion and permeability 21 and, combined with measurements of arterial input function, is used to assess physiological quantities of vessel permeability including K trans using Tofts analysis. 21, 31, 42 Here, a key change observed with use of either VEGF-trap or B20 (but not sunitinib) was complete loss of enhancement on DCE-MR images within 3 days of treatment. A previous report using a rat model of intracranial glioma tumor also shows that VEGF-trap results in a significant reduction in DCE-MRI parameters including K trans , K ep , and K v . 43 As a result of the complete shutdown of DCE enhancement with VEGF inhibition, K trans could not be analyzed accurately. Consequently, we used an alternate MRI biomarker, iAUC, which is model-independent and provides information about the blood flow, extracellular extravascular space, and vessel permeability. 31 To date, iAUC has principally been used as an MRI biomarker that distinguishes between treatment-induced necrosis and tumor recurrence in patients with GBMs. 44 Our finding of significant reduction in iAUC was linked with a significant inhibition in kinetics of contrast agent accumulation in the VEGF-trap treated tumors. iAUC also showed temporary or sustained reduction in response to sunitinib or sunitinib + RT respectively; however, the extent of iAUC reduction in response to sunitinib was not as pronounced as with VEGF-trap. Therefore, iAUC can be considered as an effective MRI biomarker reflective of changes seen in vessel permeability/ perfusion in response to AATx. Previously, we have shown that K trans can be used as a parameter of vessel permeability in response to sunitinib [41] , and in this study we similarly confirmed that iAUC is an additional reliable biomarker of vessel permeability. Moreover, in this study it appears that the reduction in iAUC was consistent with increased survival of the animals. Given that mice treated with VEGF-trap or VEGF-trap + RT survived longer than sunitinib-treated groups, iAUC also appears to correlate with overall survival, suggesting that these MRI parameters can be used as predictors of survival in response to AATx. Angiopoietins (Ang-1 and Ang-2) are involved in vascular homeostasis and maturation through their specific endothelial cell receptors Tie-1 and Tie-2. While Ang-1 reduces vessel permeability, Ang-2 exerts opposing effects resulting in dilated, destabilized, and leaky vasculature. 45 Following VEGF-trap treatment, we demonstrated an increased expression of Ang-1 in the center of the tumors, which could account for the diminished vascular permeability/perfusion and consequent reduction in enhancement seen in DCE and T 1 w + contrst.
In summary, we extend our prior findings by demonstrating that ADC accurately represents tumor cell density and as such can be used as a reliable biomarker of efficient cytotoxic therapy. Our results confirm that reduction in contrast enhancement is not an accurate reflection of tumor growth in response to AATx; rather than being an accurate measure of MVD, contrast enhancement is a reflection of an alteration in physiological parameters of tumor vascularity such as vessel perfusion and permeability. We showed that DCE-derived parameters, specifically iAUC, can differentiate the response to different classes of AATxs and predict survival of GBMs and therefore potentially predict effectiveness of AATx. We demonstrated that MRI biomarkers are specific to individual AATx agents and therefore, the use and interpretation of noninvasive MRI biomarkers to monitor the therapeutic response to AATx should be tailored in the clinical setting to the specific individual agents. Further studies are required to validate these MRI parameters in the clinical setting, where cohorts of similarly treated patients with rigorous follow-up imaging are needed.
